
Evolus (EOLS) Stock Forecast & Price Target
Evolus (EOLS) Analyst Ratings
Bulls say
Evolus is a performance beauty company with a promising outlook, as their two commercially available products - Jeuveau and Evolysse - continue to gain traction in the cash-pay aesthetic market. They are also well-positioned for competition against established players, such as Voluma and Galderma. Evolus's financials and long-term outlook are strong, with expected revenue growth and a solid pipeline. However, potential risks include a decrease in consumer spending and supply chain challenges.
Bears say
Evolus is a cash-pay medical company that specializes in aesthetic injectables such as Jeuveau and Evolysse, with a focus on targeting the millennial market. However, there are risks to their rating and price target such as potential competition, pricing pressure, and higher-than-expected operating expenses. Despite being an established brand with a 14% market share, concerns about consumer spending and commercial execution may negatively affect their growth potential in the near future.
This aggregate rating is based on analysts' research of Evolus and is not a guaranteed prediction by Public.com or investment advice.
Evolus (EOLS) Analyst Forecast & Price Prediction
Start investing in Evolus (EOLS)
Order type
Buy in
Order amount
Est. shares
0 shares